Note: Ingredients listed on restricted chemical lists
EC/CAS
220-239-6/2682-20-4
Name of the chemical
2-Methyl-2H-isothiazol-3-one
Concentration
326-00-
General Information
Version
10.01
Revision date
2023-06-23
Product name
Anaplasma vet ELISA
Product name
Anaplasma vet ELISA
Identification on the label/Trade name
ELISA Kits (see below listing)
1.2.1 Relevant identified uses
in vitro research
supplier name
Demeditec Diagnostics GmbH
Emergency telephone
+49 (0)431/71922-0
Icons in SDS
Company Information
company name
Demeditec Diagnostics GmbH
e-mail address of the competent person responsible for the Safety Data Sheet
info@demeditec.de
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H317
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
Hazard statements
see section 16 H317: May cause an allergic skin reaction. P261: Avoid breathing mist, vapours, spray. P280: Wear protective clothing, protecting gloves, eye protection. P302+352 IF ON SKIN Wash with plenty of soap and water P333+P313 If skin irritation or rash occurs Get medical advice/atten- tion. P362+P364: Take off contaminated clothing and wash it before reuse.
Adverse physicochemical, human health and environmental effects
May cause an allergic skin reaction.
2.2 Label elements
Labelling
Hazard pictograms
GHS07
Signal word
Warning
Hazardous Ingredients
2-methyl-2H-isothiazol-3-one
2.3 Other hazards
This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII Contains no PBT/vPvB substances ≥0.1% assessed in accordance with REACH Annex XIII Component 2-methyl-2H-isothiazol-3-one This substance/mixture does not meet the PBT criteria of REACH (2682-20-4) regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %